This series is designed to provide investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.
November 27, 2023
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
November 20, 2023
Next Generation Anthracycline
November 27, 2023
FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
November 14, 2023
Full Enrollment for VenoValve U.S. Pivotal Trial
October, 30, 2023
November, 1, 2023
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
NKGen Biotech Receives FDA Clearance of IND for SNK01 NK Cell Therapy to Treat Moderate Alzheimer's Disease
October, 18, 2023
Continuing Rapid Pace of
Enrollment with 229 Patients Enrolled
October, 17, 2023
Moleculin Doses First Patient in
Phase 2 Study for AML
September 27, 2023
Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement.
September 8, 2023
AREC"s ReElement Technologies Expands Executive Team
August 24, 2023
Recent Clinical Update on Potentially Pivotal Study of Berubicin for GBM
GRI Bio Enters into Asset Purchase Agreement for Sale of Legacy Asset, ADAIR
August 23, 2023
August 7, 2023
GRI Bio Presents Encouraging Preclinical Data of GRI-0803 in Lupus Nephritis
